Javelin Pharmaceuticals, Inc. (AMEX: JAV - News) announced today that its CEO, Martin J. Driscoll, and Stephen J. Tulipano, CFO, will host a conference call to discuss the Company's quarterly results for the period ending September 30, 2008. The call will be held Monday, November 10, 2008 at 8:30a.m. EST.

The Company invites all interested parties to participate. The call will be webcast and accessible live through the following URL: ir.javelinpharmaceuticals.com/events.cfm.

CONFERENCE CALL ALERT
Javelin Pharmaceuticals, Inc. Q3 2008 Earnings Call
Date: November 10, 2008
Time: 08:30m E.S.T.
Please dial: (877) 675-4757 or International (719) 325-4935

The call will be archived at the Company's website: www.javelinpharmaceuticals.com.

About Javelin Pharmaceuticals, Inc.:

With corporate headquarters in Cambridge, MA, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. The Company markets Dyloject (injectable diclofenac sodium) in the UK and has three drug candidates in US Phase 3 clinical development. For additional information about Javelin, please visit the company's website at http://www.javelinpharmaceuticals.com.

Forward Looking Statement:

This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our ability to obtain working capital, our ability to successfully develop and commercialize drug candidates, and competition from other pharmaceutical companies.